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Introduction: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness.
Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent
or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus
placebo to mitigate CIPNM in a prospective setting.
Methods: In this prospective, randomized, double-blinded and placebo-controlled trial, 38 critically ill patients with
multiple organ failure (MOF), systemic inflammatory response syndrome (SIRS)/sepsis, and early clinical signs of
CIPNM were included. Patients were randomly assigned to be treated either with IgM-enriched IVIG or placebo over
a period of three days. CIPNM was measured by the CIPNM severity sum score based on electrophysiological
stimulation of the median, ulnar, and tibial nerves on days 0, 4, 7, 14 and on the histological evaluation of muscle
biopsies on days 0 and 14 and ranged from 0 (no CIPNM) to 8 (very severe CIPNM).
Results: A total of 38 critically ill patients were included and randomized to receive either IgM-enriched IVIG
(n = 19) or placebo (n = 19). Baseline characteristics were similar between the two groups. CIPNM could not be
improved by IVIG treatment, represented by similar CIPNM severity sum scores on day 14 (IVIG vs. placebo: 4.8 ± 2.0 vs.
4.5 ± 1.8; P = 0.70). CIPNM severity sum score significantly increased from baseline to day 14 (3.5 ± 1.6 vs. 4.6 ± 1.9;
P = 0.002). After an interim analysis the study was terminated early due to futility in reaching the primary endpoint.
Conclusions: Early treatment with IVIG did not mitigate CIPNM in critically ill patients with MOF and SIRS/sepsis.
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Critical illness polyneuropathy (CIP) and critical illness
myopathy (CIM) are serious complications of severely ill
patients [1].
CIP is an acute and primarily distal axonal sensory-
motor polyneuropathy affecting mainly lower extrem-
ities and respiratory muscles [2]. As in some patients
when primarily the muscles are affected, the term
critical illness myopathy (CIM) was established [1].
However, the differentiation between CIP and CIM is
difficult. Therefore, and due to the frequent associ-
ation of both, the term critical illness polyneuropathy
and/or myopathy (CIPNM) was introduced in 2000
[3]. Moreover, electrophysiological and histological
findings of CIP and CIM disclose a significant overlap
of these two entities [4].
In prospective studies, about 60 to 80% of patients
with multiple organ failure (MOF) with or without sepsis
or systemic inflammatory response syndrome (SIRS)
presented with CIPNM [5-7]. In patients with septic
shock [8] or severe sepsis and coma [9] the prevalence
may reach up to 100%. In the majority of patients with
sepsis a combination of both CIP and CIM was de-
scribed [10].
Independent risk factors for CIPNM are, amongst
others, severity of illness, duration of MOF with or with-
out SIRS, duration of vasopressor and catecholamine
support, hyperglycemia and duration of intensive care
unit (ICU) stay [1].
The clinical features of CIP and CIM are almost identi-
cal and include muscle weakness and atrophy primarily of
the lower limbs and respiratory muscles, delayed weaning
from the respirator not explained by pulmonary or cardio-
vascular findings, and prolongation of the mobilization
phase [1]. Moreover, a number of complications, such as
pneumonia, deep vein thrombosis and pulmonary embol-
ism may be attributed - at least in part - to CIPNM [11].
On neurological examination, decreased or absent tendon
reflexes, especially with CIP, muscular atrophies and sym-
metrical flaccid tetraparesis are present [1].
The gold standards used to diagnose CIPNM are elec-
trophysiological stimulation (EPS) and muscle biopsy.
Characteristically, electromyography (EMG) and nerve
conduction velocity (NCV) studies demonstrate the
preservation of the speed of impulse in the presence of
decreased compound muscle (CMAP) and sensory nerve
(SNAP) action potential amplitudes [12]. These findings
are highly consistent with a relatively pure axonal poly-
neuropathy. Furthermore, EMG discloses signs of de-
nervation like fibrillation potentials and positive sharp
waves in a widespread distribution. For the definite diag-
nosis of CIM and to differentiate between CIP and CIM
the histological assessment of a muscle biopsy is the
preferable method [1].For CIPNM no specific pathogenic-based therapy is
proven. For prevention, sepsis should be treated with
maximum effort, including intensive insulin therapy
(IIT) [13]. Muscle relaxants and corticosteroids should
be administered at the lowest doses needed, whereas the
potentially detrimental effect of the latter has been con-
troversially discussed [14].
However, there is weak evidence from a retrospective
chart analysis of prospectively collected data, that early
IgM-enriched IVIG application may prevent CIPNM [15].
IVIG contains natural polyreactive antibodies derived
from human plasma of healthy donors directed against
endogenous and exogenous antibodies, immunomodu-
lating peptides and various cytokines [16].
The pathophysiologic rationale for using IVIG to treat
CIPNM is based on the association of CIPNM with pro-
inflammatory cytokines accompanied by increased E-
selection expression [3,17]. This favors the accumulation
of neurotoxic factors in the endoneurium and causes
extravasation of activated leukocytes both resulting in
neuron damage [18]. Furthermore, elevated cytokine
levels directly induce muscle protein damage via acti-
vation of calpain and ubiquitine-proteasome [14]. The
anti-inflammatory and immunomodulating properties of
IVIG may attenuate the local immune activation on both
the cellular and the humoral level [16].
Therefore, we aimed to investigate the use of IVIG in
the early treatment of CIPNM in critically ill patients in
a prospective, randomized, double-blinded and placebo-
controlled setting.
Material and methods
Trial design and setting
This prospective, randomized, double-blinded, placebo-
controlled trial was conducted in an eight-bed medical
ICU at the University Hospital of Vienna, Austria.
Participants
Critically ill patients with MOF (failure of two or more
organs), a SIRS/sepsis diagnosis, and first clinical evidence
for CIPNM were randomized. Organ failure was defined as
a cardiovascular system dysfunction (systolic blood pres-
sure <90 mmHg or mean arterial pressure <70 mmHg),
kidney dysfunction (urine output <0.5 ml/kg body weight/
hour for one hour, despite adequate fluid resuscitation),
respiratory system dysfunction (ratio of PaO2 to FiO2 <250
in the presence of other dysfunctional organs or systems),
hematologic dysfunction (platelet count <80.000/mm3 or
decreased by 50% in the three days preceding enrollment
in the absence of liver cirrhosis or previously known
hematological disease), or metabolic dysfunction (unex-
plained metabolic acidosis: pH <7.30 or base deficit >5.0
mmol/L in association with a plasma lactate level >1.5
times of the upper normal limit).
Brunner et al. Critical Care 2013, 17:R213 Page 3 of 10
http://ccforum.com/content/17/5/R213Clinical signs of CIPNM were defined as decreased ten-
don reflexes, signs of incipient muscular atrophy, de-
creased muscle strengths in responsive and co-operative
patients, or facial grimacing but reduced or absent move-
ment of limbs after induction of a painful stimulus by nail
bed compression as assessed by a clinical neurologist. The
diagnosis of “clinical signs of CIPNM” was met if one or
more of these features were found. The examinations were
quantified in absolute measures, as well as compared to
previous examinations of the same patient, if applicable.
Exclusion criteria were age <18 or >80 years, body
weight >135 kg (due to potentially impaired quality of
the electrophysiology examination), pregnancy or breast-
feeding, known absolute IgA-deficiency(*), known IVIG-
intolerability(*), pre-existing neuromuscular disorders(*)
(ICD-10: G70 to G73), pre-existing severe polyneu-
ropathy(*) (ICD-10: G61 to G63), known diseases of the
peripheral nervous system(*) (ICD-10: G60 and G64),
pre-existing disease of the central nervous system with
relevant impairment of the motor function(*) (ICD-10:
G10 to G13, G20 to G26, G35 to G37, G80 to G83),
relevant pulmonary edema secondary to severe heart
failure, survival expectancy <28 days based on an uncor-
rectable medical condition, moribund state with imminent
death, HIV infection in association with a last known CD4+
count of <50/mm3(*), and requirement of chronic ventilator
support for non-respiratory reasons (*). These exclusion
criteria were applied to information from the medical
history of the patient.
Interventions
Randomized patients were treated either with IgM-
enriched IVIG (Pentaglobin®, Biotest Pharma GmbH,Figure 1 Study timeline. Patients with multiple (≥2) organ failure and a d
intravenous immunoglobulins (IVIG) or human albumin (placebo) for three
(CIPNM) was assessed at baseline (Day 0) and on Day 14 by electrophysiolo
Primary endpoint was a CIPNM severity sum score on Day 14.Dreieich, Germany) or with human albumin 1% (Biotest
Pharma GmbH, Dreieich, Germany) as placebo at a dose
of 0.25 g/kg body weight/day as a continuous intravenous
infusion at a rate of 2 g/h over a period of three days
(Figure 1). Treatment was started immediately after all
patient selection criteria, including clinical signs of
CIPNM, were met.
Outcomes
The primary outcome was to assess the effect of early
IVIG versus placebo to mitigate CIPNM in critically ill
patients as assessed by the CIPNM severity sum score
on Day 14. CIPNM severity sum score is a combined
endpoint consisting of the CIP and the CIM scores
determined on Day 0 (baseline) and after treatment
(Day 14).
CIP was determined by EPS of the median, ulnar and
tibial nerves on days 0, 4, 7 and 14 using a Nicolet
Viking IV (Nicolet Biomedical, Fenton, MO, USA) appa-
ratus. CIP was graded based on the CMAP amplitude
size according to the following scheme. CMAP ampli-
tude ≥4,000 μV was considered as normal (score = 0),
CMAP amplitude ≥3,000 μV and <4,000 μV as mild CIP
(score = 1), CMAP amplitude ≥2,000 μV and <3,000 μV
as moderate CIP (score = 2), CMAP amplitude ≥1,000
μV and <2,000 μV as severe CIP (score = 3), and CMAP
amplitude <1,000 μV as very severe CIP (score = 4). For
each day the nerve with the highest CIP score value was
used for further calculations.
CIM was semi-quantitatively scored by an independent
blinded neuropathologist according to the histological
and ultrastructural findings of the skeletal muscle biopsy
specimens taken on days 0 and 14.iagnosis of SIRS/sepsis were randomized to be treated either with
consecutive days. Critical illness polyneuropathy and/or myopathy
gical stimulation and histological assessment of a muscle biopsy.
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from the Musculus vastus lateralis by the same clinician
according to a standardized protocol. In case of a second
biopsy (on Day 14), the biopsy was performed on the
contralateral muscle. The biopsy site was on the straight
line between the great trochanter and the lateral condyle
of the femur exactly 20 cm proximal of the lateral
condyle. First, a small sterile field was prepared and local
anesthetic was applied into the (sub)cutaneous area up
to the Fascia lata. After the incision of the cutis at a 90°
angle the area up to the Fascia lata was dissected out
under visual control. Second, the muscle was biopsied
using a Bergstroem muscle biopsy needle (Stille, Stockholm,
Sweden).
Muscle tissue was snap frozen and a small part fixed
in glutaraledhyde and embedded in resin. The panel of
stainings, including HE, ATPase (pH 4.3), Oil-Red O,
PAS, Gomori Trichrome, NADH and combined COX-
SDH, was performed on the cross-cut frozen sections.
Furthermore, sections were stained with antibodies against
myosin slow and fast (Novocastra, Milton Keynes, UK,
1:100), γ sarcoglykan (Novocastra, 1:200), and N-terminal
utrophin (Novocastra, 1:200). Thick sections of 4 μm were
cut of the resin embedded tissue and stained with tolui-
dine blue.
The quantification of myopathy was based on charac-
teristic features of acute myopathy in intensive care,
namely type II fibre atrophy (numerous scattered angu-
lar, atrophic fibers identified as type 2 fibers by ATPase
and myosin stains), muscle necrosis, and selective loss of
myosin filaments and scored as follows [4,14,19]: no
signs of myopathy (score = 0), signs of mild myopathy
(score = 1), signs of moderate myopathy (score = 2),
signs of severe myopathy (score = 3), and signs of very
severe myopathy (score = 4).
Hence, the CIPNM severity sum score consisting of
the CIP and CIM scores determined on days 0 and 14
ranged from 0 (no CIM, no CIP) to 8 (very severe CIP,
very severe CIM).
Secondary outcomes were to assess the effect of early
IVIG versus placebo on mortality from any cause within a
28-day period and length of the ICU stay. Furthermore,
we investigated the course of CIPNM from baseline to
Day 14 in all patients.Sample size
The software PASS 11 (NCSS, Kaysville, UT, USA) was
used for sample size calculation. Group sample sizes of
2 × 30 patients achieve 81% power to detect a difference
in CIPNM sum score of 1.5 between the intervention
group (estimated score of 4.0) and the control group (es-
timated score of 2.5) given standard deviations of 2.0
and at a two-sided significance level (alpha) of 0.05 usinga Mann-Whitney test assuming that the actual distribu-
tions are equal.
Randomization
The software “Randlist” (University of Gottingen, Germany)
was used for randomization. Patients were stratified by
Acute Physiology and Chronic Health Evaluation III
(APACHE III) scores (low risk: ≤60; high risk: >60) and
random permuted blocks within strata were generated
(block size = 6). A person not otherwise involved in this
study randomized patients 1:1.
IVIG and human albumin were supplied in a form in
which no differentiation between verum and placebo
was possible. The study medication was linked to the
patient numbers for identification according to the
randomization list. Participants and care providers were
blinded to the treatment.
Statistical methods
Data are presented as mean ± standard deviation,
median (25th to 75th percentile) or count and relative
frequency. Differences between the study groups were
assessed using the Fisher’s exact or the Student’s t-test,
as appropriate. We performed a number of sensitivity
analyses using different metrics for the CIPNM, inclu-
ding the difference from baseline to study end, yielding
virtually unchanged results (data not shown). To assess
the course of CIPNM we calculated the differences of
the CIPNM severity sum scores regardless of the group
and compared it versus 0 in a one-sided t-test. We used
the Kruskal-Wallis-Test to compare non-parametric
variables between patients with signs of CIP only, CIM
only and combined CIP/CIM. For data management and
calculations we used Excel 2011 and Stata 11.0 for Mac
(Stata Corporation, College Station, TX, USA). A two-
sided P-value ≤0.05 was generally considered statistically
significant.
Ethical approval
The study was approved by the Ethics Committee of the
Medical University of Vienna. According to Austrian law
and the guidelines of the research ethics committee,
written informed consent was obtained from patients
after they regained consciousness.
Results
A total of 38 critically ill patients with MOF, a SIRS/sep-
sis diagnosis and clinical signs of CIPNM were recruited
between December 2004 and April 2009 and rando-
mized to either receive IVIG or placebo (Figure 2). The
study team determined during the first interim analysis
that the trial be terminated due to futility in reaching
the primary endpoint. This decision was based on simi-
lar CIPNM scores in the intervention and control group
Figure 2 Screening and randomization scheme. Patients were screened for multiple (≥2) organ failure and a SIRS/sepsis diagnosis. Patients
meeting these criteria were assessed by a neurologist for clinical signs of critical illness polyneuropathy and/or myopathy (CIPNM). Patients with
clinical signs of CIPNM were randomized to receive either intravenous immunoglobulins (IVIG) or placebo.
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treated with IVIG and 19 with placebo for three con-
secutive days, respectively. Treatment was started at a
median five (three to seven) days after the onset of
SIRS/sepsis. There were no significant differences in
baseline characteristics between the two study groups.
CIP, CIM and CIPNM scores in both study groups were
markedly increased on baseline confirming the signs of
CIPNM found in the clinical examination (Table 1).
The primary outcome CIPNM severity sum score on
Day 14, as assessed by a combination of EPS of the
ulnar, median and tibial nerves and histological examin-
ation of a muscle biopsy were not statistically different
between the two groups (Figure 3a).
Moreover, neither isolated findings of EPS on days 0, 4,
7 and 14 (CIP score) nor of the histological examinationof muscle biopsies on days 0 and 14 (CIM score) differed
between the two groups on any of the time points
(Figures 3a, b). Similarly, the secondary outcomes 28-day
mortality and length of ICU stay were similar between the
groups (Table 1). CIPNM deteriorated significantly from
Day 0 to Day 14 regardless of the group allocation
(Figure 3a).
At baseline, 16% of the patients (5/32) presented with
increased CIP scores only, 16% (5/32) with increased
CIM scores only, and 66% (21/32) with a combination of
increased CIM and CIP scores. Thus, 97% of the ana-
lyzed patients (31/32) were diagnosed with CIPNM at
baseline based on EPS and muscle histology findings.
In six patients, either the CIM or CIP score was not
available, and one patient did not show signs of CIM or
of CIP at baseline. Age, length of ICU stay, Sequential






Admission reason Number of patients
Respiratory failure 7 8 1.00
Cardiopulmonary resuscitation 1 2 1.00
Sepsis/septic shock 9 8 1.00
Cardiogenic shock 1 1 1.00
Coma 1 0 1.00
Age (years) 61 ± 11 66 ± 12 0.18
Gender (female/male) (7/12) (10/9) 0.52
BMI (kg/m2) 28 ± 5 28 ± 6 0.94
SOFA score 11 ± 4 11 ± 5 0.88
APACHE III score 96 ± 28 96 ± 24 0.99
Mortality on Day 14
(non-survivors (%))
3 (16%) 3 (16%) 1.00
Mortality on Day 28
(non-survivors (%))
5 (26%) 6 (32%) 1.00
Length of ICU stay (days) 30 ± 16 27 ± 13 0.66
CIP score on Day 0 2.6 ± 1.5 2.0 ± 1.3 0.26
CIM score on Day 0 1.1 ± 0.8 1.4 ± 0.8 0.27
CIPNM severity sum score
on Day 0
3.6 ± 1.8 3.4 ± 1.5 0.71
C-reactive protein (mg/dL)
on Day 0
13 ± 11 13 ± 8 0.99
Fibrinogen (mg/dL) on Day 0 462 ± 186 563 ± 192 0.11
Leukocytes (G/L) on Day 0 19.4 ± 10.3 18.6 ± 8.7 0.78
Data are means ± SD or absolute counts. APACHE III, Acute Physiology and
Chronic Health Evaluation III; BMI, body mass index; CIM, Critical illness
myopathy; CIP, Critical illness polyneuropathy; CIPNM, Critical illness
polyneuropathy and/or myopathy; IVIG, intravenous immunoglobulin; SOFA,
Sequential Organ Failure Assessment score.
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III score and mortality were similar between patients
having CIM, CIP or combined CIP/CIM.
EPS and histological assessment could not be perfor-
med at some time points due to the following reasons:
patient’s death (histology on Day 14 (6 times) and EPS
on days 4, 7, 14 (10 times)), withdrawn consent (histo-
logy on day 14 (once)), prone position (EPS on days 4, 7,
14 (3 times)), insufficient muscle tissue in biopsy (histo-
ogy on days 0 and 14 (3 times)), necrotizing fasciitis
(EPS on days 0, 4 (twice)), dislocated fracture (EPS on
days 4, 7, 14 (3 times)), or logistic reasons (EPS on days
4, 7 (18 times)).
Discussion
CIPNM is a serious complication of critically ill patients
leading to muscle weakness and weaning failure. To
date, no specific treatment has been proven in random-
ized controlled trials to prevent or mitigate CIPNM [1].As there is evidence for a role of immune mechanisms
in CIPNM [3], Wijdicks et al. administered IVIG in
three patients, without beneficial effects [20]. However,
in a retrospective analysis of 33 patients early adminis-
tration of IgM-enriched IVIG was suggested to prevent
CIPNM [15].
The present study is the first prospective, randomized,
double-blinded, placebo-controlled trial assessing the
impact of IgM-enriched IVIG on CIPNM. To achieve a
potentially optimal effect of IVIG, we included only
severely ill patients with MOF, a SIRS/sepsis diagnosis
and clinical signs of CIPNM.
However, IVIG did not mitigate CIPNM in the critic-
ally ill patients in the present trial. Neither CIP as deter-
mined by EPS of three nerves on days 0, 4, 7 and 14 nor
CIM as assessed by the histological examination of
muscle biopsies on days 0 and 14 were different in the
IVIG group compared to the controls at any time point.
Moreover, length of ICU stay and mortality were similar
in both groups.
More than two-thirds of the patients presented with
both increased CIM and CIP scores while 16% had
either elevated CIP or CIM scores. Thus, 97% of the pa-
tients (31/32) presented with CIPNM at baseline based
on EPS and muscle histology findings. This is compar-
able to patients with severe sepsis [10]. As CIP and CIM
are overlapping diseases, the CIP (CIM) score does not
necessarily reflect severity of CIP (CIM) only, but should
be seen as a marker of the severity of CIPNM.
Mohr et al. found some evidence in a retrospective
chart analysis of IVIG being able to prevent CIPNM in
critically ill patients using EPS [15]. Based on the
retrospective character of their analysis, the evidence
has been regarded as weak and is in contrast with find-
ings of our prospective, randomized, double-blinded
placebo-controlled trial. However, Mohr et al. started
their IVIG treatment within 24 hours after onset of
sepsis/multi organ failure and did not wait for the first
clinical signs of CIPNM. As we administered IVIG only
after the first clinical evidence of CIPNM at median five
(three to seven) days after the start of the respective
SIRS/sepsis episode, these two studies are not entirely
comparable.
Rationale for the treatment strategy
The pathophysiologic rationale for using IVIG to treat
CIPNM in the present study is based on the association
of CIPNM with pro-inflammatory cytokines, such as
TNF-α, IFN-γ, IL-1, and IL-12 accompanied by increa-
sed E-selection expression [3,17]. This is suggested to
promote the adhesion of leukocytes to endothelial-cells
and extravasation of activated leukocytes within the
endoneurial space. The increased cytokine production
leads to enhanced vascular permeability favoring the
Figure 3 Critical illness polyneuropathy, myopathy and critical illness polyneuropathy and/or myopathy scores. Critical illness polyneuropathy
and/or myopathy (CIPNM) severity sum score was not different on Day 14 between the intravenous immunoglobulin (IVIG) and placebo treatment
group based on electrophysiological stimulation and muscle histology. CIPNM severity sum score deteriorated from baseline (Day 0) to Day 14 in
both groups (a). Critical illness polyneuropathy (CIP) was similar in the IVIG and placebo treatment group at all times based on electrophysiological
stimulation (b). Critical illness myopathy (CIM) scores were similar in the two groups based on muscle histology (c). A two-sided P-value ≤0.05 was
considered statistically significant (*).
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causing neuron damage [18]. Furthermore, elevated
cytokine levels directly induce muscle protein damage
via activation of calpain and ubiquitine-proteasome [14].
The anti-inflammatory and immunomodulating proper-
ties of IVIG are mediated by regulating the production,
release and function of pro-inflammatory cytokines and
have been successfully used in numerous autoimmune
and inflammatory diseases [16,21,22].
The use of IgM-enriched IVIG was based on the
potential superiority over standard IVIG as seen in
sepsis treatment and on the analysis of Mohr et al., who
suggested a beneficial effect of IgM-enriched IVIG in the
prevention of CIPNM [15,23].
Standard IVIG has been safely administered intra-
venously at daily doses of 0.40 g/kg body weight overfive days in patients with Guillain-Barré syndrome [24].
Mohr et al. administered IgM-enriched IVIG at doses of
0.3 g/kg body weight daily over three days [15]. How-
ever, the manufacturer recommends that IgM-enriched
IVIG be administered at a maximum dose of 0.25 g/kg
body weight daily for three consecutive days, which is
also the common dosage for the treatment of severe
sepsis [25]. Therefore, we decided to administer IgM-
enriched IVIG at a dose of 0.25 g/kg body weight daily
for three consecutive days. Nevertheless, we cannot rule
out a potential benefit with higher doses of IgM-
enriched IVIG regarding the treatment of CIPNM.
Strengths and limitations
It is desirable to have a clinical endpoint like the Medical
Research Council (MRC) scale for muscle strength to
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assessment depends on patient's cooperation and cannot
be performed in patients who are not fully awake [26].
Patients in our study were severely ill, represented by
MOF, SIRS/sepsis and high SOFA/APACHE III scores.
The vast majority was fully or partly sedated (87% at
baseline; 50% on Day 14) and/or intubated/tracheoto-
mized (95% at baseline; 84% on Day 14). Therefore, clin-
ical assessment of the muscle weakness using the MRC
scale was not feasible in the majority of our patients. At
baseline only 5 of 38 patients (3 in the placebo, 2 in the
IVIG group) were cooperative enough to allow the clinical
assessment of muscle strengths using the MRC scale.
This is similar to Routsi et al., who only could deter-
mine the MRC score in one-third of their patients
although their patients were less ill than those in the
present study [26]. Thus, as a clinical endpoint was not
feasible, we regarded the CIPNM severity sum score,
based on serial EPS and two muscle biopsies, as the
most appropriate method of assessing the course of
CIPNM in critically ill patients who are not fully awake.
A total of 106 patients fulfilling the screening criteria
(SIRS/Sepsis and MOF) were evaluated by a neurologist
in order to only randomize patients with clinical signs of
CIPNM. This evaluation was challenging as the majority
of the patients was not fully awake. However, unlike the
MRC scale assessment, its aim was not to measure
CIPNM using a metric scale but to select patients with
an advanced stage of CIPNM. One-third (38 of 106) of
patients met these criteria. CIPNM was confirmed in
97% (37 of 38) of patients at baseline based on EPS and
muscle histology findings with relatively high CIPNM
sum scores. Therefore, we regard the initial clinical
evaluation as a valid tool to specifically select patients
with an advanced stage of CIPNM, whereas the sensiti-
vity of this evaluation may have been rather low [1].
The differentiation between CIP and CIM is often not
possible in critically ill patients by EPS alone. This short-
coming also could be compensated for by using the
CIPNM severity sum score. Routsi et al., who suggested
that electrical muscle stimulation may prevent CIPNM,
used only a clinical score for muscle strength to assess
CIPNM and, therefore, could not differentiate between
CIP and CIM [26]. Another method to make a distinc-
tion between CIP and CIM is direct muscle stimulation
[27]. However, as muscle biopsy is regarded as the gold
standard, we did not use direct muscle stimulation in
our study [4].
Van den Berghe et al. found a reduced incidence of
CIPNM in a pre-planned subgroup analysis of critically
ill patients treated with IIT compared to conventional
insulin therapy. Similarly, no differentiation between CIP
and CIM was feasible in their study, as no histological
assessment was done [13].It has been controversially discussed if discrimination
between CIP and CIM is reasonable. However, exact dif-
ferential diagnosis between these two entities leads to
better prognostic information regarding long term dis-
ability [1,28]. CIM in combination with CIP is associated
with a more severe weakness and longer ICU length of
stay than CIM alone [29]. Moreover, CIM has a better
long-term prognosis than CIP [30].
The main limitation of the present trial is the relatively
small number of critically ill patients included in our trial
prone to type II errors. Although we did not see any dif-
ferences in the outcomes between the groups, this cannot
entirely rule out a (small) effect of IVIG on CIPNM.
Furthermore, not all EPS or muscle biopsy evaluations
could be performed as scheduled. The recruitment
period of 4.5 years is rather long for a single-center trial
and this potentially influenced the results. The slow
recruiting is attributed to the very specific inclusion cri-
teria, based on which only patients with a two-or-more
organ failure, SIRS/sepsis, and clinical evidence for
CIPNM could be included. To minimize the potential
bias of the relatively long recruitment period we ensured
that all procedures were carried out by the same team
throughout the study period.
Although EPS and muscle biopsy are the methods of
choice of assessing nerve and muscle damage in CIPNM
[4], a combination of both (CIPNM sum score) as used
in the present study has never been validated to be
superior. Therefore, we also provide separate results of
EPS and muscle biopsy assessment which do not differ
from the CIPNM sum score (Figure 3). The CIPNM
sum score should be further validated in future trials for
determining the specificity and sensitivity of CIPNM in
critically ill patients.
Another limitation may have been the use of the “CIM
score” based on the histological assessment of muscle
biopsies. Although histological assessment is the diag-
nostic method of choice to evaluate myopathy in critic-
ally ill patients the grading of the “CIM score” is only
semi-quantitative and has not been validated before.
Muscle biopsy is regarded as safe and well tolerated in
critically ill patients but it is still an invasive procedure
[31]. Therefore, we suggest that muscle biopsies should
primarily be used in clinical trials. Unclear muscle weak-
ness and inconclusive electrophysiological findings may
justify muscle biopsy in the clinical routine.
Ultrasound has been successfully used to reliably
measure muscle mass in critically ill patients [32]. How-
ever, at the start of enrollment (December 2004), this
information was not yet available. Furthermore, the
patients included in our trial were more severely ill than
in the trial of Gruther et al. As tissue edema is common
in severely ill patients, the assessment of the muscle
mass using ultrasound may be challenging. Nevertheless,
Brunner et al. Critical Care 2013, 17:R213 Page 9 of 10
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tional outcome in future trials.
Patients with clinical unapparent polyneuropathy or
mild polyneuropathy were eligible for enrollment, as we
did not expect an effect on the primary outcome.
We hypothesize that the following circumstances may
be responsible for the lack of effect of IVIG. First, we de-
cided to include patients that were already presenting
with clinical signs of CIPNM at an early stage to achieve
a maximal effect of IVIG. However, the application of
IVIG at an even earlier time point - when the first signs
of CIPNM can be verified only using electrophysiology
measures may result in improved effects of IVIG. This
was similarly observed in patients with severe sepsis,
who had a significantly improved survival rate when
IVIGs were administered early compared to at a more
advanced phase of sepsis [33].
Thus, earlier or even prophylactic application of IVIG
may show better effects of IVIG regarding the preven-
tion or mitigation of CIPNM, since a short, albeit cru-
cial, time period may pass between first nerve and/or
muscle fiber damage and first demonstrable electro-
physiological changes, not to mention the first clinical
signs, chosen as inclusion criterion in our study. How-
ever, a prophylactic treatment had required the inclusion
of a lot more patients.
Potentially, a beneficial effect of IVIG on CIPNM
may only be seen months after ICU discharge and
was still concealed on Day 14 when we assessed the
primary outcome. Due to patients lost to follow-up,
this requires the inclusion of a higher number of
patients.
Furthermore, the pathophysiology of CIPNM is
complex and a multimodal cause is postulated. This
includes alterations of the local immunity, decreased
microcirculation of peripheral nerves, increased gener-
ation and deficient scavenging of reactive oxygen spe-
cies, enhanced permeability for neurotoxic factors
into the endoneurium, direct muscular protein break-
down and acquired channelopathy [34]. However,
IVIG has only a relatively limited point of action by
modulating the local immunity [16]. Thus, a multi-
modal therapy approach may be necessary to improve
CIPNM.Conclusions
This prospective, randomized, double-blinded, placebo-
controlled trial showed that early treatment with IVIG
does neither significantly improve CIPNM nor influ-
ence length of ICU stay or mortality in critically ill
patients. CIPNM deteriorated during the course of dis-
ease in critically ill patients with MOF and a diagnosis
of SIRS/sepsis.Key message
 Early treatment with IVIG does not improve
CIPNM in critically ill patients with MOF and
SIRS/sepsis.
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